Last reviewed · How we verify

Flixotide plus Foradil — Competitive Intelligence Brief

Flixotide plus Foradil (Flixotide plus Foradil) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Inhaled corticosteroid/long-acting beta-2 agonist combination (ICS/LABA). Area: Respiratory/Pulmonology.

phase 3 Inhaled corticosteroid/long-acting beta-2 agonist combination (ICS/LABA) Glucocorticoid receptor (fluticasone); Beta-2 adrenergic receptor (formoterol) Respiratory/Pulmonology Small molecule Live · refreshed every 30 min

Target snapshot

Flixotide plus Foradil (Flixotide plus Foradil) — Mundipharma Research Limited. Flixotide plus Foradil is a combination inhaler that delivers a corticosteroid (fluticasone) to reduce airway inflammation and a long-acting beta-2 agonist (formoterol) to relax airway smooth muscle.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Flixotide plus Foradil TARGET Flixotide plus Foradil Mundipharma Research Limited phase 3 Inhaled corticosteroid/long-acting beta-2 agonist combination (ICS/LABA) Glucocorticoid receptor (fluticasone); Beta-2 adrenergic receptor (formoterol)
fluticasone/salmeterol fluticasone/salmeterol Hull University Teaching Hospitals NHS Trust marketed Inhaled corticosteroid/long-acting beta-2 agonist combination (ICS/LABA) Glucocorticoid receptor (fluticasone); beta-2 adrenergic receptor (salmeterol)
Fluticasone/Formoterol Fluticasone/Formoterol Mundipharma Korea Ltd marketed Inhaled corticosteroid/long-acting beta-2 agonist combination (ICS/LABA) Glucocorticoid receptor (fluticasone); beta-2 adrenergic receptor (formoterol)
SFC SFC GlaxoSmithKline marketed Inhaled corticosteroid/long-acting beta-2 agonist combination (ICS/LABA) Glucocorticoid receptor (fluticasone); Beta-2 adrenergic receptor (salmeterol)
Advair 250 Advair 250 Milton S. Hershey Medical Center marketed Inhaled corticosteroid/long-acting beta-2 agonist combination (ICS/LABA) Glucocorticoid receptor (fluticasone); beta-2 adrenergic receptor (salmeterol)
Foster BDP/Formoterol Foster BDP/Formoterol Chiesi Farmaceutici S.p.A. marketed Inhaled corticosteroid/long-acting beta-2 agonist combination (ICS/LABA) Glucocorticoid receptor (beclomethasone); beta-2 adrenergic receptor (formoterol)
Drug: Budesonide/formoterol (Symbicort Turbuhaler Drug: Budesonide/formoterol (Symbicort Turbuhaler AstraZeneca marketed Inhaled corticosteroid/long-acting beta-2 agonist combination (ICS/LABA) Glucocorticoid receptor (budesonide); beta-2 adrenergic receptor (formoterol)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Inhaled corticosteroid/long-acting beta-2 agonist combination (ICS/LABA) class)

  1. Chiesi Farmaceutici S.p.A. · 5 drugs in this class
  2. AstraZeneca · 5 drugs in this class
  3. Mundipharma Research Limited · 4 drugs in this class
  4. GlaxoSmithKline · 2 drugs in this class
  5. Milton S. Hershey Medical Center · 1 drug in this class
  6. Mundipharma Korea Ltd · 1 drug in this class
  7. SkyePharma AG · 1 drug in this class
  8. Actavis Inc. · 1 drug in this class
  9. University Hospital, Antwerp · 1 drug in this class
  10. Allergy and Asthma Center of El Paso · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Flixotide plus Foradil — Competitive Intelligence Brief. https://druglandscape.com/ci/flixotide-plus-foradil. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators: